Maze Therapeutics, Inc. Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest in USD from Q4 2023 to Q3 2025
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.
-
Summary
-
Maze Therapeutics, Inc. quarterly Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest history and growth rate from Q4 2023 to Q3 2025.
- Maze Therapeutics, Inc. Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest for the quarter ending September 30, 2025 was $379M.
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Quarterly (USD)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, YoY Quarterly Growth (%)